RARP Offers Favorable Long-Term Outcomes
WASHINGTON, D.C.—Robot-assisted radical prostatectomy (RARP) for localized prostate cancer (PCa) offers favorable intermediate- and long-term oncologic outcomes, according to researchers.
Their conclusion is based on an analysis of data from the largest RARP series with the longest follow-up.
Craig Rogers, MD, and colleagues at the Henry Ford Health System (HFHS) in Detroit, studied 3,671 of 4,047 patients who underwent RARP from September 2001 to December 2008. Patients had a mean follow-up time of 33.8 months. Nine patients (0.3%) died from PCa and metastatic disease developed in 18 patients (0.5%). Actuarial three- and five-year biochemical recurrence-free survival was 91.3% and 87%, respectively. Actuarial three- and five-year cancer-specific survival was 99.8% and 99.6%, Dr. Rogers' group reported at the American Urological Association 2011 annual meeting.
The strong predictors of biochemical recurrence were high-grade disease and non-organ-confined disease on final pathology, said Dr. Rogers, Director of Robotic Renal Surgery at the HFHS' Vattikuti Urology Institute.